ArticleCurrent infectious disease reports2008
Strongyloides stercoralis infection in the immunocompromised host.
Article in Current infectious disease reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 106 citations in OpenAlex.
- In-silico design of a multi-epitope vaccine candidate against Strongyloides stercoralis.BMC infectious diseases · 2026Article
- Strongyloidiasis Beyond the Tropics: Updated Epidemiological Evidence from a Historically Endemic Region in Spain.Tropical medicine and infectious disease · 2026Article
- An Overlooked Cause of Generalized Edema: A Case ofClinical case reports · 2025Article
- Article
- Strongyloides Hyperinfection Syndrome and Disseminated Disease with Negative Serology.The American journal of tropical medicine and hygiene · 2024Article
- ChronicJournal of medical microbiology · 2024Article
- High-throughput sequencing ofParasitology · 2024Article
- Progress towards the implementation of control programmes for strongyloidiasis in endemic areas: estimation of number of adults in need of ivermectin for strongyloidiasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024Article
- Fatal Disseminated Strongyloidiasis in an Immunosuppressed Patient During COVID-19 Pandemic.Acta parasitologica · 2023Article
- Steroid-induced Strongyloidiasis with Cholestasis Post-COVID-19 Pneumonia.Oman medical journal · 2023Article
- Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review.The American journal of tropical medicine and hygiene · 2023Article
- From past to present: opportunities and trends in the molecular detection and diagnosis of Strongyloides stercoralis.Parasites & vectors · 2023Review
- Strongyloides and COVID-19: Challenges and Opportunities for Future Research.Tropical medicine and infectious disease · 2023Review
- Evaluation of larval surface antigens from infective larvae of Strongyloides venezuelensis for the serodiagnosis of human strongyloidiasis.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023Article
- Prevalence and Associated Risk Factors of Intestinal Parasitic Infections: A Population-Based Study in Phra Lap Sub-District, Mueang Khon Kaen District, Khon Kaen Province, Northeastern Thailand.Tropical medicine and infectious disease · 2022Article
- Review
- Article
- Strongyloides Hyperinfection Causing Gastrointestinal Bleeding and Bacteremia in an Immunocompromised Patient.Cureus · 2021Article
- Sarcoidosis, steroids and Strongyloides-what's the catch?Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2020Article
- Prevalence of Strongyloides stercoralis infection and hyperinfection syndrome among renal allograft recipients in Central Europe.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Strongyloides stercoralis is an intestinal nematode acquired in the tropics or subtropics. Most often, it causes chronic, asymptomatic infection, but a change in immune status can increase parasite numbers, leading to hyperinfection syndrome, dissemination, and death if unrecognized. Corticosteroid use is most commonly associated with hyperinfection syndrome. Diagnosis of Strongyloides infection is based on serology and serial stool examinations for larvae. The treatment of choice for chronic, asymptomatic infection is oral ivermectin. Alternative pharmacologic agents include albendazole and thiabendazole. For hyperinfection syndrome, ivermectin remains the drug of choice, though therapy duration must be individualized with the end point being complete parasite eradication. Recurrent strongyloidiasis should prompt an evaluation for human T-cell lymphotropic virus type 1 coinfection. No test of cure is currently available, although immunoglobulin G antibody levels have been shown to decline within 6 months of successful treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.